Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals proposed sale notice (Form 144): A notice lists a proposed sale of 6,000 shares of Common Stock with a transaction date shown as 04/01/2026 and Nasdaq as the market. The filing also records a prior sale of 6,000 shares on 03/03/2026 for $1,118,613.32.
Jazz Pharmaceuticals PLC: The Vanguard Group files an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will now report holdings separately in reliance on SEC Release No. 34-39538.
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.
Jazz Pharmaceuticals plc Executive Vice President and Chief Financial Officer Philip L. Johnson reported a tax-related share disposition. On March 5, 2026, 2,615 ordinary shares were withheld at $188.69 per share to cover tax obligations from the vesting of previously granted restricted stock units. After this withholding, he directly held 59,608 ordinary shares.
Jazz Pharmaceuticals plc SVP, Technical Operations Mary Elizabeth Henderson reported a tax-related share disposition. On March 5, 2026, she disposed of 1,394 ordinary shares to satisfy tax obligations from vesting restricted stock units, at a weighted average price of $186.747 per share.
The shares were sold in multiple transactions at prices ranging from $186.1633 to $186.7558. After these transactions, Henderson directly owned 27,334 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc executive reports tax-related share disposition. EVP and Chief Commercial Officer Samantha Pearce had 2,503 Ordinary Shares withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. After this tax-withholding transaction, she directly owns 50,272 Ordinary Shares.
Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.
Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions. On March 9, 2026, she completed an open-market sale of 1,287 ordinary shares at a weighted average price of $182.94, leaving 6,512 shares directly owned afterward.
On March 5, 2026, she disposed of 1,436 ordinary shares at $186.7723 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, resulting in 7,799 shares directly owned following that transaction.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a tax-related share transaction. On March 5, 2026, 7,065 ordinary shares were disposed of at $188.69 per share to satisfy tax obligations from vesting restricted stock units. After this withholding transaction, she directly owned 152,630 ordinary shares.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition. On March 5, 2026, 5,000 Ordinary Shares of Jazz were withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This was recorded as a tax-withholding disposition rather than an open-market sale, and Patil’s directly held stake after the transaction was 53,818 Ordinary Shares.